Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi taps Oncodesign's macrocycles for kinase targets

This article was originally published in Scrip

Executive Summary

Sanofi is to tap fellow French firm Oncodesign for its macrocyclic small molecule kinase inhibitor discovery expertise. Oncodesign stands to receive up to €130 million in technology access fee and discovery, development, regulatory and commercial milestones as well as low-single digit royalties under the four-year agreement. The extent to which the deal is back-loaded is not clear.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts